Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 5Thoracic 4Dermatologic 4Gastrointestinal 3Breast 2Head & Neck 1Gynecologic 1

Conditions

Breast Neoplasms 23Carcinoma, Non-Small-Cell Lung 8Triple Negative Breast Neoplasms 5Neoplasm Metastasis 5Colorectal Neoplasms 5Lung Neoplasms 4Breast Neoplasms, Male 3Stomach Neoplasms 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Neoplasms 2Mesothelioma 2Melanoma 2Head and Neck Neoplasms 2Carcinoma, Renal Cell 2Sarcoma 1Salivary Gland Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1NSCLC 1Mesothelioma, Malignant 1Meningeal Carcinomatosis 1Lymphoma, Non-Hodgkin 1Lymphoma 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Fallopian Tube Neoplasms 1Esthesioneuroblastoma, Olfactory 1Esophageal Neoplasms 1Carcinoma, Transitional Cell 1

Interventions

pembrolizumab 36Nivolumab 16Cyclophosphamide 12atezolizumab 8Docetaxel 8Magnetic Resonance Spectroscopy 7Paclitaxel 6Everolimus 6spartalizumab 5fludarabine 5durvalumab 5Specimen Handling 5Ipilimumab 5cabozantinib 4avelumab 4Trastuzumab 4Radiotherapy 4Radiosurgery 4Oxaliplatin 4Leucovorin 4temsirolimus 3pazopanib 3aldesleukin 3Taxes 3Sunitinib 3Psychiatric Rehabilitation 3Interleukin-2 3Immune Checkpoint Inhibitors 3Gemcitabine 3Fluorouracil 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoma, Renal Cell × Pemetrexed × Breast × Clear all
NCT02419495 2025-06-04

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

M.D. Anderson Cancer Center

Phase 1 Terminated
221 enrolled
BreastDermatologicGenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT02983045 2023-03-13

PIVOT-02

Nektar Therapeutics

Phase 1/2 Completed
557 enrolled 22 charts
BreastDermatologicGastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Melanoma, Neoplasm Metastasis, Stomach Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡